Insight Molecular Diagnostics
Business Services · Tennessee, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2 International Plz Ste 510, Nashville, ...Phone Number
(615) 255-8880Website
www.imdxinc.comRevenue
$5.9 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Insight Molecular Diagnostics
iMDx specializes in precision diagnostics for oncology and transplantation, providing innovative solutions that cater to the needs of researchers, clinicians, and healthcare systems. Their product offerings include molecular diagnostic tools designed for early detection, treatment guidance, and research applications. The company is committed to advancing precision medicine and improving patient outcomes through actionable insights and scalable diagnostic solutions. iMDx aims to democratize access to molecular diagnostic testing, creating sustainable value for healthcare providers and patients alike.Explore more
Insight Molecular Diagnostics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Insight Molecular Diagnostics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Insight Molecular Diagnostics launches new products
Earning: See what the market has to say on Insight Molecular Diagnostics recently announced quarterly report
Insight Molecular Diagnostics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Insight Molecular Diagnostics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Insight Molecular Diagnostics
Website visits: Recent activity has been detected on your website
Check if Insight Molecular Diagnostics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Insight Molecular Diagnostics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Insight Molecular Diagnostics has new funding data
Recommended Actions
Reach out to Masked Content who joined Insight Molecular Diagnostics as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Insight Molecular Diagnostics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Insight Molecular Diagnostics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Insight Molecular Diagnostics.
Insight Molecular Diagnostics Tech Stack
A closer look at the technologies used by Insight Molecular Diagnostics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Earnings
continues to target an average cash burn of about $6 million per quarter until its commercial launch next year, with expectations of higher burn in Q3 before coming back down in Q4. The company noted that the biggest factors affecting cash management are its clinical trial and the purchase of discounted instruments to support the trial at partner sites.
Earnings, Financial Planning, Business Finance, Finance, Financial Strategy
Earnings
reported sales of $24,000 worth of first-generation Raft Assured IQ kits in Q2. The company began shipping second-generation kits to customers in June, with initial kits provided as free samples for lab validation.
Earnings, Product Launch, Finance, Healthcare Technology
Earnings
Earnings, Accounting, Financial Reporting, Business Finance, Finance
Insight Molecular Diagnostics News & Media
iMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 Conference
NASHVILLE, Tenn., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report second quarter 2026 financial results after the market closes on Monday, August 10, 2026. iMDx will host a live Zoom webinar to discuss the company's financial results at 2:00 pm PT / 5:00 pm ET that same day.iMDx GraftAssure Assay Guides Use of Potentially Kidney-Graft-Saving Drug in New Lancet Group Publication
NASHVILLE, Tenn., July 23, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) ("iMDx") today highlighted the publication of a new study in The Lancet Regional Health – Europe, part of the Lancet Group, demonstrating the potential role of donor-derived cell-free DNA (dd-cfDNA) monitoring to help guide treatment decisions for kidney transplant patients.Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio
NASHVILLE, Tenn., July 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today highlighted a favorable new Medicare policy supporting expanded coverage for donor-derived cell-free DNA (dd-cfDNA) testing in transplant care.IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper
NASHVILLE, Tenn., June 29, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that its Chief Science Officer, Prof. Dr. Ekkehard Schuetz. M.D., Ph.D., has published his 200th scientific article.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Insight Molecular Diagnostics
Sign Up For FreeTo access detailed company insights
iMDx specializes in precision diagnostics for oncology and transplantation, providing innovative solutions that cater to the needs of researchers, clinicians, and healthcare systems. Their product offerings include molecular diagnostic tools designed for early detection, treatment guidance, and research applications. The company is committed to adv... Read More
